Treating Liposarcomas Using HIV Protease Inhibitors

**DESCRIPTION**

Liposarcoma is the second most common adult soft tissue sarcoma, accounting for approximately 20% of all sarcomas. Sarcomas consist of a heterogeneous group of histologically distinct malignancies that arise from mesenchymal tissues. Liposarcomas are malignant tumors derived from primitive or embryonal lipoblastic cells and are histologically distinct from Kaposi’s sarcoma, an indolent vascular tumor. Metastatic liposarcoma is associated with an extremely poor prognosis, with average 5-year survivals ranging from 70% to as low as 25% depending on the makeup of the tumor.

This technology covers the use of HIV protease inhibitors such as Nelfinavir for the treatment of Liposarcomas. These protease inhibitors selectively inhibit liposarcoma clonogenicity.

**KEY ASPECTS**

- The protease inhibitors that can be used to treat Liposarcomas include Nelfinavir, Indinavir and Ritonavir
- This protease inhibitor treatment may be used in conjunction with standard chemotherapy and surgical resection of the sarcoma

**PUBLISHED DATA**


**INTELLECTUAL PROPERTY**

<table>
<thead>
<tr>
<th>Title</th>
<th>US Patent Number</th>
<th>Issued</th>
</tr>
</thead>
<tbody>
<tr>
<td>Method of Using Protease Inhibitors for the Treatment of Liposarcomas</td>
<td>7,812,034</td>
<td>10/12/2010</td>
</tr>
</tbody>
</table>

**CONTACT**

Matthew Grunseth, M.B.S.
Manager, Office of Technology Licensing
Telephone: (626) 471-7221 | Email: mgrunseth@coh.org

This material is a summary of public domain and non-confidential City of Hope information. Additional material may be disclosed under a confidentiality agreement.